Crain's New York16h
New York Blood Center researchers make breakthrough on sickle cell disease
Researchers at the New York Blood Center have made a breakthrough in understanding the body’s autoimmune response to sickle ...
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
The Week14h
How public-private partnerships are making bone marrow transplants accessible and affordable
Bone marrow transplantation is a costly procedure. Depending on the type of transplant the rate may vary from ₹7 lakh to ₹50 ...
Verywell Health on MSN6h
What Is Bone Marrow and Why Is It Important?
Medically reviewed by Gagandeep Brar, MD Bone marrow is the deep, interior portion of your bone. Your bone marrow, which has ...
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
Topeka WIBW-TV on MSN3h
Weekend blood drive supports people with sickle cell disease
The Sickle Cell Blood Drive with the American Red Cross runs 9 a.m. to 2 p.m. Saturday at Apostolic Church of Jesus Christ, 2420 SE Bellview Ave.
Black History Month: Sickle cell disease research underway at Yale
News 8 is once again honoring Black history by looking at health care and the racial disparities many report facing.
phillyvoice.com20h
Blood transfusions at the scene save lives. But ambulances are rarely equipped to do them
More than 60,000 people bleed to death every year from injuries caused by car crashes and other emergencies. Many of these ...